Vivus Drug Patent Portfolio
Vivus owns 3 orange book drugs protected by 18 US patents Given below is the list of Vivus's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8580299 | Escalating dosing regimen for effecting weight loss and treating obesity | 14 Jun, 2029 | Active |
| US8580298 | Low dose topiramate/phentermine composition and methods of use thereof | 15 May, 2029 | Active |
| US8895057 | Escalating dosing regimen for effecting weight loss and treating obesity | 09 Jun, 2028 | Active |
| US8895058 | Low dose topiramate/phentermine composition and methods of use thereof | 09 Jun, 2028 | Active |
| US9011905 | Low dose topiramate/phentermine composition and methods of use thereof | 09 Jun, 2028 | Active |
| US9011906 | Escalating dosing regimen for effecting weight loss and treating obesity | 09 Jun, 2028 | Active |
| US8221747 | Stable pancreatic enzyme compositions | 20 Feb, 2028 | Active |
| US8562978 | Stable digestive enzyme compositions | 20 Feb, 2028 | Active |
| US8562979 | Stable digestive enzyme compositions | 20 Feb, 2028 | Active |
| US8562980 | Stable digestive enzyme compositions | 20 Feb, 2028 | Active |
| US8562981 | Stable digestive enzyme compositions | 20 Feb, 2028 | Active |
| US6656935 | Aromatic nitrogen-containing 6-membered cyclic compounds | 27 Apr, 2025 | Expired |
| US7501409 | Preparations for oral administration | 05 May, 2023 | Expired |
| US7056890 | Combination therapy for effecting weight loss and treating obesity | 14 Jun, 2020 | Expired |
| US7553818 | Combination therapy for effecting weight loss and treating obesity | 14 Jun, 2020 | Expired |
| US7659256 | Combination therapy for effecting weight loss and treating obesity | 14 Jun, 2020 | Expired |
| US7674776 | Combination therapy for effecting weight loss and treating obesity | 14 Jun, 2020 | Expired |
| US6071537 | Anticonvulsant derivatives useful in treating obesity | 23 Jun, 2017 | Expired |
Latest Legal Activities on Vivus's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Vivus.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 03 Jan, 2024 | US8221747 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Oct, 2022 | US9011905 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Oct, 2022 | US9011906 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 May, 2022 | US8895057 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 May, 2022 | US8895058 (Litigated) |
|
Expire Patent
Critical
| 11 Apr, 2022 | US7674776 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 25 Oct, 2021 | US7674776 (Litigated) |
|
Expire Patent
Critical
| 02 Aug, 2021 | US7553818 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Apr, 2021 | US8580299 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Apr, 2021 | US8580298 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 07 Apr, 2021 | US8562979 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 07 Apr, 2021 | US8562978 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 07 Apr, 2021 | US8562980 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 07 Apr, 2021 | US8562981 |
|
Maintenance Fee Reminder Mailed
Critical
| 15 Feb, 2021 | US7553818 (Litigated) |
Vivus's Family Patents
Vivus Drug List
Given below is the complete list of Vivus's drugs and the patents protecting them.
1. Pancreaze
Pancreaze is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8221747 | Stable pancreatic enzyme compositions |
20 Feb, 2028
(2 years from now)
| Active |
| US8562978 | Stable digestive enzyme compositions |
20 Feb, 2028
(2 years from now)
| Active |
| US8562979 | Stable digestive enzyme compositions |
20 Feb, 2028
(2 years from now)
| Active |
| US8562980 | Stable digestive enzyme compositions |
20 Feb, 2028
(2 years from now)
| Active |
| US8562981 | Stable digestive enzyme compositions |
20 Feb, 2028
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pancreaze's drug page
2. Qsymia
Qsymia is protected by 11 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8580299 | Escalating dosing regimen for effecting weight loss and treating obesity |
14 Jun, 2029
(3 years from now)
| Active |
| US8580298 | Low dose topiramate/phentermine composition and methods of use thereof |
15 May, 2029
(3 years from now)
| Active |
| US8895057 | Escalating dosing regimen for effecting weight loss and treating obesity |
09 Jun, 2028
(2 years from now)
| Active |
| US8895058 | Low dose topiramate/phentermine composition and methods of use thereof |
09 Jun, 2028
(2 years from now)
| Active |
| US9011905 | Low dose topiramate/phentermine composition and methods of use thereof |
09 Jun, 2028
(2 years from now)
| Active |
| US9011906 | Escalating dosing regimen for effecting weight loss and treating obesity |
09 Jun, 2028
(2 years from now)
| Active |
| US7056890 | Combination therapy for effecting weight loss and treating obesity |
14 Jun, 2020
(5 years ago)
| Expired |
| US7553818 | Combination therapy for effecting weight loss and treating obesity |
14 Jun, 2020
(5 years ago)
| Expired |
| US7659256 | Combination therapy for effecting weight loss and treating obesity |
14 Jun, 2020
(5 years ago)
| Expired |
| US7674776 | Combination therapy for effecting weight loss and treating obesity |
14 Jun, 2020
(5 years ago)
| Expired |
| US6071537 | Anticonvulsant derivatives useful in treating obesity |
23 Jun, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qsymia's drug page
3. Stendra
Stendra is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6656935 | Aromatic nitrogen-containing 6-membered cyclic compounds |
27 Apr, 2025
(8 months ago)
| Expired |
| US7501409 | Preparations for oral administration |
05 May, 2023
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Stendra's drug page